Skip To Main Content

KRAS G12C

(RG6330)

Solid Tumor

Phase I

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

NCT04449874